Evidence map›Paper›PMID 21118961›Full record

ArticleCancer research2010

Sp100 as a potent tumor suppressor: accelerated senescence and rapid malignant transformation of human fibroblasts through modulation of an embryonic stem cell program.

Dmitri G Negorev, Olga V Vladimirova, Andrew V Kossenkov, Elena V Nikonova, Renee M Demarest, Anthony J Capobianco, Michael K Showe, Frank J Rauscher, Louise C Showe, Gerd G Maul

RetractedOpen access · bronzeAbstract readRetracted Publication
In one paragraph

Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Nuclear domain 10 of the viral aspect.World journal of virology · 2013
    Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Dmitri G NegorevThe Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
Olga V Vladimirova
Andrew V Kossenkov
Elena V Nikonova
Renee M Demarest
Anthony J Capobianco
Michael K Showe
Frank J Rauscher
Louise C Showe
Gerd G Maul
The Wistar Institute · USUniversity of Miami · US

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
TRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3M
HDAC Inhibitors and CTCLR01CA132098 · NCI · WISTAR INSTITUTE · PI SHOWE, LOUISE C. · 2009 to 2013
$2.0M
MECHANISMS OF FETAL MEMBRANE RUPTURER01HD034612 · NICHD · VIRGINIA COMMONWEALTH UNIVERSITY · PI STRAUSS, JEROME F · 1996 to 2010
$1.8M
EARLY INTERACTIONS OF DNA VIRUSES AND HOSTR01AI041136 · NIAID · WISTAR INSTITUTE · PI MAUL, GERD G · 1998 to 2005
$1.8M
Characterization of a Potential Nuclear Protein DepotR01GM064691 · NIGMS · WISTAR INSTITUTE · PI MAUL, GERD G · 2002 to 2005
$1.3M
Early interactions of DNA viruses and hostR56AI041136 · NIAID · WISTAR INSTITUTE · PI KAUFMAN, RUSSEL E. · 2008 to 2009
$828k
Comprehensive genomics using the Illumina Beadstation 500S10RR024693 · NCRR · WISTAR INSTITUTE · PI SHOWE, LOUISE C. · 2008 to 2008
$405k
EARLY INTERACTIONS OF DNA VIRUSES AND HOSTR21AI041136 · NIAID · WISTAR INSTITUTE · PI MAUL, GERD G · 1997 to 1997
–
VIRUS DNA TARGETING MECHANISM--THE TARGETR21GM057599 · NIGMS · WISTAR INSTITUTE · PI MAUL, GERD G · 1998 to 1999
–
NCI NIH HHS CA 010815NCI NIH HHS CA 132098NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA132098NCI NIH HHS T32 CA009171NCRR NIH HHS S10 RR024693NIAID NIH HHS AI 41136NIAID NIH HHS R01 AI041136NIAID NIH HHS R56 AI041136NICHD NIH HHS HD 34612NICHD NIH HHS R01 HD034612NIGMS NIH HHS GM57599NIGMS NIH HHS R01 GM064691
6 · The paper itself

Abstract

Identifying the functions of proteins, which associate with specific subnuclear structures, is critical to understanding eukaryotic nuclear dynamics. Sp100 is a prototypical protein of ND10/PML nuclear bodies, which colocalizes with Daxx and the proto-oncogenic PML. Sp100 isoforms contain SAND, PHD, Bromo, and HMG domains and are highly sumoylated, all characteristics suggestive of a role in chromatin-mediated gene regulation. A role for Sp100 in oncogenesis has not been defined previously. Using selective Sp100 isoform-knockdown approaches, we show that normal human diploid fibroblasts with reduced Sp100 levels rapidly senesce. Subsequently, small rapidly dividing Sp100 minus cells emerge from the senescing fibroblasts and are found to be highly tumorigenic in nude mice. The derivation of these tumorigenic cells from the parental fibroblasts is confirmed by microsatellite analysis. The small rapidly dividing Sp100 minus cells now also lack ND10/PML bodies, and exhibit genomic instability and p53 cytoplasmic sequestration. They have also activated MYC, RAS, and TERT pathways and express mesenchymal to epithelial transdifferentiation (MET) markers. Reintroduction of expression of only the Sp100A isoform is sufficient to maintain senescence and to inhibit emergence of the highly tumorigenic cells. Global transcriptome studies, quantitative PCR, and protein studies, as well as immunolocalization studies during the course of the transformation, reveal that a transient expression of stem cell markers precedes the malignant transformation. These results identify a role for Sp100 as a tumor suppressor in addition to its role in maintaining ND10/PML bodies and in the epigenetic regulation of gene expression.

Indexed as

AnimalsAntigens, NuclearAutoantigensBlotting, WesternCells, CulturedCell Transformation, NeoplasticCellular SenescenceEmbryonic Stem CellsEpithelial-Mesenchymal TransitionFibroblastsGene Expression ProfilingHEK293 CellsHumansMaleMiceMice, NudeAntigens, NuclearAutoantigensCALCOCO2 protein, humanMYC protein, humanNuclear ProteinsPML protein, humanPromyelocytic Leukemia ProteinProto-Oncogene Proteins c-mycras ProteinsSP100 protein, humanTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID21118961
PMCPMC3059726
OpenAlexW2120494127

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.